| Patent application number | Description | Published |
|---|
| 20080275220 | METHOD FOR STABILIZING A PROTEIN - The invention relates to a method for stabilizing an aqueous protein solution against exogenous stress and to the use of a container for stabilizing an aqueous protein solution. | 11-06-2008 |
| 20090068196 | Pharmaceutical formulation of an antibody against IL13Ralpha1 - Pharmaceutical formulations of an antibody against IL13Rα | 03-12-2009 |
| 20090162352 | ANTIBODY FORMULATION - The present invention relates to a pharmaceutical formulation comprising an anti-CD20 antibody. The formulation may additionally comprise a buffer, a surfactant and/or an isotonicity agent. | 06-25-2009 |
| 20090208509 | Pharmaceutical formulation of an antibody against IL-1R - Pharmaceutical formulation of an antibody against IL-1R (interleukin-1 receptor), a process for the preparation and uses of the formulation. | 08-20-2009 |
| 20100098712 | Pharmaceutical formulation of an antibody against OX40L - Pharmaceutical formulations of an antibody against OX40L and processes for making the same. | 04-22-2010 |
| 20100158919 | Pharmaceutical Composition - The present invention relates to an anti-IGF-1R human monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof | 06-24-2010 |
| 20110044977 | Subcutaneous anti-HER2 antibody formulations and uses thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 02-24-2011 |
| 20110070225 | Beta antibody parenteral formulation - The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation. Furthermore, corresponding uses are described. | 03-24-2011 |
| 20110076273 | Highly Concentrated Pharmaceutical Formulations - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 03-31-2011 |
| 20110152188 | PHARMACEUTICAL COMPOSITIONS OF IGF/I PROTEINS - The present invention relates to a pharmaceutical composition, comprising an Insulin-like growth factor I (IGF-I) protein as active pharmaceutical ingredient (API), a tonicity agent and a buffer. This composition may be administered as injection or infusion and is especially useful for the treatment, prevention and/or delay of progression of neurodegenerative disorders, in particular Alzheimer's Disease (AD), a motor neuron disease (MND), in particular amyotrophic lateral sclerosis (ALS) or Spinal Muscular Atrophy (SMA) or a Muscular Dystrophy (MD), in particular Duchenne Muscular Dystrophy (DMD) or Myotonic Dystrophy (MMD). | 06-23-2011 |
| 20110158987 | NOVEL ANTIBODY FORMULATION - This invention relates to a pharmaceutical formulation of an antibody against Epidermal Growth Factor Receptor (EGFR), a process for the preparation and uses of the formulation. | 06-30-2011 |
